BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets…
A groundbreaking study led by a pair of researchers from Israel and involving research teams in several countries has discovered…
LIXTE recently announced advances in its approach to cancer therapy through its proprietary compound LB-100 Alongside clinical development news, LIXTE is…
ETST operates as an active strategic holding company, acquiring and optimizing businesses through direct management and governance. The company’s core…
HeartBeam was included in a report published by Modern Healthcare that highlighted companies that achieved meaningful regulatory milestones or demonstrated forward momentum.…
Many times, a diagnosis of lung cancer comes late because the early symptoms may be dismissed since they are so…
One of the key advantages of photodynamic therapy is its selectivity. Soligenix is advancing HyBryte(TM), or SGX301, designed for the…
While people have been quick to blame health insurers for the skyrocketing cost of health care in the U.S., the…
LIXTE Biotechnology recently acquired Liora Technologies, and the acquisition includes Liora’s proprietary LiGHT system This system provides several advantages over…
A planned preclinical study testing a light-activated therapy that helps to kill residual brain cancer cells after a patient has undergone surgery…